Chinese medicine herbal treatment based on syndrome differentiation improves the overall survival of patients with unresectable hepatocellular carcinoma

Ya-nan Man; Xiao-hui Liu; Xiong-zhi Wu

doi:10.1007/s11655-014-1767-9

Your Location：

Home >

Browse articles >

Chinese medicine herbal treatment based on syndrome differentiation improves the overall survival of patients with unresectable hepatocellular carcinoma

Updated：2021-08-27

- Chinese medicine herbal treatment based on syndrome differentiation improves the overall survival of patients with unresectable hepatocellular carcinoma
- Chinese Journal of Integrative Medicine Vol. 21, Issue 1, Pages: 49-57(2015)
- Affiliations：
  
  Zhong-Shan-Men Inpatient Department, National Clinical Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital,Tianjin,China
- Author bio：
- Funds：
  
  Supported by National Natural Science Foundation of China (No. 81173376), and New Century Excellent Talent, China (No. NCET-11-1068)
- DOI：10.1007/s11655-014-1767-9
  CLC：
- Published：2015，
  
  Published Online：24 December 2014，
Scan for full text
Man, Yn., Liu, Xh. & Wu, Xz. Chinese medicine herbal treatment based on syndrome differentiation improves the overall survival of patients with unresectable hepatocellular carcinoma., Chin. J. Integr. Med. 21, 49–57 (2015). https://doi.org/10.1007/s11655-014-1767-9

Ya-nan Man, Xiao-hui Liu, Xiong-zhi Wu. Chinese medicine herbal treatment based on syndrome differentiation improves the overall survival of patients with unresectable hepatocellular carcinoma. [J]. Chinese Journal of Integrative Medicine 21(1):49-57(2015)
Man, Yn., Liu, Xh. & Wu, Xz. Chinese medicine herbal treatment based on syndrome differentiation improves the overall survival of patients with unresectable hepatocellular carcinoma., Chin. J. Integr. Med. 21, 49–57 (2015). https://doi.org/10.1007/s11655-014-1767-9 DOI：

Ya-nan Man, Xiao-hui Liu, Xiong-zhi Wu. Chinese medicine herbal treatment based on syndrome differentiation improves the overall survival of patients with unresectable hepatocellular carcinoma. [J]. Chinese Journal of Integrative Medicine 21(1):49-57(2015) DOI： 10.1007/s11655-014-1767-9.

摘要

To investigate the effects of Chinese medicine (CM) herbal treatment based on syndrome differentiation on patients with unresectable hepatocellular carcinoma (HCC). A total of 94 patients with unresectable HCC were reviewed between June 2008 and June 2011. Survival analysis was performed between patients who received CM with/without non-curative antitumor treatments of Western medicine (WM) (CM group

30 cases) and patients who were not treated with CM but with non-curative antitumor treatments of WM or supportive treatment alone (non-CM group

64 cases). Then

survival analysis was performed between patients treated with CM combined with non-curative antitumor treatments of WM (combination therapy group

25 cases) and patients with non-curative antitumor treatments of WM alone (non-curative antitumor treatments group of WM

52 cases). The survival analysis was performed by Kaplan-Meier method and prognostic factors for overall survival (OS) were assessed by the Cox proportional hazards regression model. The median survival time (MST)

1- and 2-year survival rates of the CM group and the non-CM group were 36 months

76.7%

56.1% and 12 months

48.4%

26.6%

respectively. The Log-rank test revealed significant difference between the two groups in OS (P<0.01). Cox proportional multivariate analysis revealed that CM was an independent favorable prognostic factor for OS. The MST

1- and 2-year survival rates of combination therapy group and non-curative antitumor treatments group of WM were 36 months

76.0%

55.5% and 13 months

55.8%

30.8%

respectively. There was significant difference in OS between the two groups (P=0.004). CM herbs based on syndrome differentiation have positive effects on survival of patients with unresectable HCC. Furthermore

combination therapy of CM and WM are recommended in HCC treatment.

Abstract

30 cases) and patients who were not treated with CM but with non-curative antitumor treatments of WM or supportive treatment alone (non-CM group

64 cases). Then

survival analysis was performed between patients treated with CM combined with non-curative antitumor treatments of WM (combination therapy group

25 cases) and patients with non-curative antitumor treatments of WM alone (non-curative antitumor treatments group of WM

1- and 2-year survival rates of the CM group and the non-CM group were 36 months

76.7%

56.1% and 12 months

48.4%

26.6%

1- and 2-year survival rates of combination therapy group and non-curative antitumor treatments group of WM were 36 months

76.0%

55.5% and 13 months

55.8%

30.8%

combination therapy of CM and WM are recommended in HCC treatment.

关键词

hepatocellular carcinomaChinese MedicineSyndrome Differentiationcombination therapyprognosis

Keywords

hepatocellular carcinomaChinese MedicineSyndrome Differentiationcombination therapyprognosis

references

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69–90.

Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907–1917.

Yuen MF, Hou JL, Chutaputti A. Hepatocellular carcinoma in the Asia pacific region. J Gastroenterol Hepatol 2009;24:346–353.

World Health Organization, International Agency for Research on Cancer. GLO-BOCAN 2008. http://globocan.iarc.fr

Lau WY, Lai EC. The current role of radiofrequency ablation in the management of hepatocellular carcinoma: a systematic review. Ann Surg 2009;249:20–25.

Sakon M, Nagano H, Nakamori S, Dono K, Umeshita K, Murakami T, et al. Intrahepatic recurrences of hepatocellular carcinoma after hepatectomy: analysis based on tumor hemodynamics. Arch Surg 2002;137:94–99.

Lee YK, Kim SU, Kim DY, Ahn SH, Lee KH, Lee DY, et al. Prognostic value of α-fetoprotein and des-gamma-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization. BMC Cancer 2013;13:5.

Wu MC. Chinese medicine in prevention and treatment of liver cancer: function, status and existed problems. J Chin Integr Med (Chin) 2003;1:163–164.

Li MD, Qiao CX, Qin LP, Zhang JY, Ling CQ. Application of traditional Chinese medicine injection in treatment of primary liver cancer: a review. J Tradit Chin Med 2012;32:299–307.

Lee JK, Kim JH, Shin HK. Therapeutic effects of the oriental herbal medicine Sho-saiko-to on liver cirrhosis and carcinoma. Hepatol Res 2011;41:825–837.

Lin LZ, Zhou DH, Liu K, Wang FJ, Lan SQ, Ye XW. Analysis on the prognostic factors in patients with large hepatocarcinoma treated by Shentao Ruangan Pill and hydroxycamptothecine. Chin J Integr Tradit West Med (Chin) 2005;25:8–11.

Wu P, Dugoua JJ, Eyawo O, Mills EJ. Traditional Chinese medicines in the treatment of hepatocellular cancers: a systematic review and meta-analysis. J Exp Clin Cancer Res 2009;28:112.

Zhai XF, Chen Z, Li B, Shen F, Fan J, Zhou WP, et al. Traditional herbal medicine in preventing recurrence after resection of small hepatocellular carcinoma: a multicenter randomized controlled trial. J Integr Med 2013;11:90–100.

National Comprehensive Cancer Network. Hepatobiliary cancers (version 2.2012). National Comprehensive Cancer Network, Inc. http://www.nccn.org/

Takuma Y, Nouso K, Makino Y, Gotoh T, Toshikuni N, Morimoto Y, et al. Outcomes after curative treatment for cryptogenic cirrhosis-associated hepatocellular carcinoma satisfying the Milan criteria. J Gastroenterol Hepatol 2011;26:1417–1424.

Chow LW, Loo WT, Sham JS, Cheung MN. Radix bupleuri containing compound (KY88 liver-livo) induces apoptosis and production of interleukin-4 and tumor necrosis factor-alpha in liver cancer cells in vitro. Am J Chin Med 2004;32:185–193.

Ong ES, Len SM, Lee AC. Differential protein expression of the inhibitory effects of a standardized extract from Scutellariae radix in liver cancer cell lines using liquid chromatography and tandem mass spectrometry. J Agric Food Chem 2005;53:8–16.

Zhang SX, Zhu C, Ba Y, Chen D, Zhou XL, Cao R, et al. Gekko-sulfated glycopeptide inhibits tumor angiogenesis by targeting basic fibroblast growth factor. J Biol Chem 2012;287:13206–13215.

Yan ZC, Chen D, Wu XZ, Xie GR, Ba Y, Yan Z. Effects of aqueous extracts of Aconitum carmichaeli, Rhizoma bolbostemmatis, Phytolacca acinosa, Panax notoginseng and Gekko swinhonis Guenther on Bel-7402 cells. World J Gastroenterol 2007;13:2743–2746.

Wang XL, Ma F, Wu XZ. Anticancer effects of 5-fluorouracil combined with warming and relieving cold phlegm formula on human breast cancer. Chin J Integr Med 2012;18:599–604.

Ding X, Zhu FS, Li M, Gao SG. Induction of apoptosis in human hepatoma SMMC-7721 cells by solamargine from Solanum nigrum L. J Ethnopharmacol 2012;139:599–604.

Zheng GY, Xin HL, Li B, Xu YF, Yi TJ, Ling CQ. Total saponin from root of Actinidia valvata Dunn prevents the metastasis of human hepatocellular carcinoma cells. Chin J Integr Med 2012;18:197–202.

Liao MH, Huang JW, Zhang T, Wu H. Transarterial chemoembolization in combination with local therapies for hepatocellular carcinoma: a meta-analysis. PLoS One 2013;8:e68453.

Wang N, Guan Q, Wang K, Zhu B, Yuan W, Zhao P, et al. TACE combined with PEI versus TACE alone in the treatment of HCC: a meta-analysis. Med Oncol 2011;28:1038–1043.

Ni JY, Liu SS, Xu LF, Sun HL, Chen YT. Transarterial chemoembolization combined with percutaneous radiofrequency ablation versus TACE and PRFA monotherapy in the treatment for hepatocellular carcinoma: a meta-analysis. J Cancer Res Clin Oncol 2013;139:653–659.

Xu LF, Sun HL, Chen YT, Ni JY, Chen D, Luo JH, et al. Large primary hepatocellular carcinoma: transarterial chemoembolization monotherapy versus combined transarterial chemoembolization-percutaneous microwave coagulation therapy. J Gastroenterol Hepatol 2013;28:456–463.

Yan S, Xu D, Sun B. Combination of radiofrequency ablation with transarterial chemoembolization for hepatocellular carcinoma: a meta-analysis. Dig Dis Sci 2013;58:2107–2113.

Boige V, Raoul JL, Pignon JP, Bouché O, Blanc JF, Dahan L, et al. Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial. Br J Cancer 2007;97:862–867.

Bobbio-Pallavicini E, Porta C, Moroni M, Bertulezzi G, Civelli L, Pugliese P, et al. Epirubicin and etoposide combination chemotherapy to treat hepatocellular carcinoma patients: a phase II study. Eur J Cancer 1997;33:1784–1788.

Lee JO, Lee KW, Oh DY, Kim JH, Im SA, Kim TY, et al. Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma. Ann Oncol 2009;20:1402–1407.

Nakamura M, Nagano H, Marubashi S, Miyamoto A, Takeda Y, Kobayashi S, et al. Pilot study of combination chemotherapy of S-1, a novel oral DPD inhibitor, and interferon-α for advanced hepatocellular carcinoma with extrahepatic metastasis. Cancer 2008;112:1765–1771.

Uka K, Aikata H, Mori N, Takaki S, Kawakami Y, Azakami T, et al. Combination therapy of oral fluoropyrimidine anticancer drug S-1 and interferon alpha for HCC patients with extrahepatic metastases. Oncology 2008;75:8–16.

Ueshima K, Kudo M, Nagai T, Tatsumi C, Ueda T, Takahashi S, et al. Combination therapy with S-1 and pegylated interferon alpha for advanced hepatocellular carcinoma. Oncology 2008;75(Suppl):106–113.

Abou-Alfa GK, Johnson P, Knox JJ, Capanu M, Davidenko I, Lacava J, et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA 2010;304:2154–2160.

Ma HQ, Zhang YJ, Wang QJ, Li YQ, He J, Wang H, et al. Therapeutic safety and effects of adjuvant autologous RetroNectin activated killer cell immunotherapy for patients with primary hepatocellular carcinoma after radiofrequency ablation. Cancer Biol Ther 2010;9:903–907.

Weng DS, Zhou J, Zhou QM, Zhao M, Wang QJ, Huang LX, et al. Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas. J Immunother 2008;31:63–71.

Huang ZM, Li W, Li S, Gao F, Zhou QM, Wu FM, et al. Cytokine-induced killer cells in combination with transcatheter arterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma patients. J Immunother 2013;36:287–293.

Hoffmann K, Glimm H, Radeleff B, Richter G, Heining C, Schenkel I, et al. Prospective, randomized, double-blind, multi-center, phase III clinical study on transarterial chemoembolization (TACE) combined with sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation—HeiLivCa [ISRCTN24081794]. BMC Cancer 2008;8:349.

Yu Y, Lang QB, Chen Z, Li BQ, Yu CQ, Zhu DZ, et al. The efficacy for unresectable hepatocellular carcinoma may be improved by transcatheter arterial chemoembolization in combination with a traditional Chinese herbal medicine formula: a retrospective study. Cancer 2009;115:5132–5138.

Chen Z, Chen HY, Lang QB, Li B, Zhai XF, Guo YY, et al. Preventive effects of Jiedu Granules combined with cinobufacini injection versus transcatheter arterial chemoembolization in post-surgical patients with hepatocellular carcinoma: a casecontrol trial. Chin J Integr Med 2012;18:339–344.

Dong XL, Gong Y, Chen ZZ, Wang YJ. Delisheng Injection (得力生注射液) a Chinese medicinal compound, enhanced the effect of cis-platinum on lung carcinoma cell line PGCL3. Chin J Integr Med 2014;20:286–291.

Chen YH, Hao LJ, Hung CP, Chen JW, Leu SF, Huang BM. Apoptotic effect of cisplatin and cordycepin on OC3 human oral cancer cells. Chin J Integr Med 2014;20:624–632.

Yeung YP, Lo CM, Liu CL, Wong BC, Fan ST, Wong J. Natural history of untreated nonsurgical hepatocellular carcinoma. Am J Gastroenterol 2005;100:1995–2004.

Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of850 patients. Cancer 1985;56:918–928.

FULL TEXT LINK

More>

Views

103

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Clinical study on long-term overall survival of advanced non-small-cell lung cancer patients treated with Chinese medicine and western medicine

Chinese medicine syndrome distribution of chronic hepatitis b virus carriers in immunotolerant phase

Effect of Longbishu Capsule (癃闭舒胶囊) plus doxazosin on benign prostatic hyperplasia: A randomized controlled trial

Potential of renal pathology on refining syndrome typing of Chinese medicine in IgA nephropathy

Preventive effects of Jiedu Granules (解毒颗粒) combined with Cinobufacini Injection (华蟾素注射液) versus transcatheter arterial chemoembolization in post-surgical patients with hepatocellular carcinoma: A case-control trial

Related Author

No data

Related Institution

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Integrated Traditional Chinese and Western Medicine, Peking University Cancer Hospital & Institute

Traditional Chinese Medicine & Acupuncture Department, The Third Affiliated Hospital of Sun Yet-sen University

Graduate School of China Academy of Chinese Medical Sciences

Department of Andrology, Xiyuan Hospital, China Academy of Chinese Medical Sciences

Department of Urology and Andrology, Affiliated Hospital of Chengdu University of Traditional Chinese Medicine

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰